Literature DB >> 6664228

Levallorphan methyl iodide (SR 58002), a potent narcotic antagonist with peripheral selectivity superior to that of other quaternary compounds.

M Dragonetti, A Bianchetti, R Sacilotto, A Giudice, N Ferrarese, C Cattaneo, L Manara.   

Abstract

The peripheral selectivity of the newer quaternary narcotic antagonist levallorphan methyl iodide (SR 58002) was found superior in mice to those of the previously available compounds N-allyl levallorphan (CM 32191), N-methyl nalorphine (MNph) and N-methyl naloxone (MNx). SR 58002 and MNph were the most potent (ID50, mg/kg s.c., 3.6 and 3.7) in preventing constipation by s.c. morphine (charcoal meal). Antinociception (hot-plate) of s.c. morphine was completely prevented by MNx, MNph and CM 32191 (ID50, mg/kg s.c., 1.6, 8.6 and 15.2) but only partially antagonized by 30 mg/kg s.c. SR 58002. Constipation elicited centrally by intracerebroventricular (i.c.v.) morphine was prevented by either s.c. MNx or MNph but not by SR 58002 or CM 32191, up to 60 mg/kg.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6664228     DOI: 10.1016/0024-3205(83)90545-3

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  4 in total

1.  Peripheral sympatho-inhibitory cardiovascular effects of opioid peptides in anaesthetized rabbits.

Authors:  B Szabo; L Hedler; C Schurr; K Starke
Journal:  Br J Pharmacol       Date:  1988-07       Impact factor: 8.739

2.  Swim-stress-induced antinociception in young rats.

Authors:  H C Jackson; I Kitchen
Journal:  Br J Pharmacol       Date:  1989-03       Impact factor: 8.739

3.  ICI 204448: a kappa-opioid agonist with limited access to the CNS.

Authors:  J S Shaw; J A Carroll; P Alcock; B G Main
Journal:  Br J Pharmacol       Date:  1989-04       Impact factor: 8.739

4.  [Constipation after tilidine/naloxone and tramadol in comparison to codeine. A dose response study in human volunteers].

Authors:  E Freye; B Rosenkranz; B Neruda
Journal:  Schmerz       Date:  1996-10-28       Impact factor: 1.107

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.